Related Experiment Video

Updated: Nov 21, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.0K

Prenatal methadone exposure and child developmental outcomes in 2-year-old children

Terri A Levine1, Alison Davie-Gray2, Hyun Min Kim3

  • 1Department of Pediatric Newborn Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.

Developmental Medicine and Child Neurology
|January 19, 2021
PubMed

Insights

Children born to mothers using methadone maintenance therapy show developmental delays in motor, cognitive, and language skills by age two. Postnatal factors significantly contribute to these pervasive developmental difficulties, highlighting the need for comprehensive support.

Area of Science:

  • Developmental Psychology
  • Neonatal Abstinence Syndrome Research
  • Maternal Opioid Treatment Studies

Background:

  • Opioid use during pregnancy poses significant risks to fetal development.
  • Methadone maintenance therapy is a common treatment for opioid dependence during pregnancy.
  • Understanding developmental outcomes in offspring exposed to methadone is crucial for early intervention.

Purpose of the Study:

  • To assess developmental outcomes in children born to mothers receiving methadone maintenance.
  • To identify pre- and postnatal risk factors impacting child development in this population.
  • To compare developmental trajectories with a non-exposed control group.

Main Methods:

  • Longitudinal study of 100 infants born to methadone-maintained mothers and 110 controls up to age 2 years.
  • Data collection included perinatal exposure information and child assessments at 2 years.
  • Assessments covered neuromotor function, cognition, language, and emotional/behavioral regulation.

Main Results:

  • Opioid-exposed children exhibited lower motor, cognitive, and language scores.
  • Poorer regulation in self, emotional, eating/feeding, and sensory processing was observed.
  • Postnatal parental and family factors explained 40-52% of the between-group outcome differences.

Conclusions:

  • Children exposed to opioids in utero demonstrate pervasive developmental difficulties by age 2.
  • Adverse pregnancy and socio-environmental exposures significantly influence these challenges.
  • Specialist prenatal care and robust postnatal intervention support are essential for high-risk families.
Abstract

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

470
Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats11:01

Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats

Published on: December 14, 2014

10.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
108
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
509
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.7K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
555
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K